Pag-aaral pangklinika para sa Obesity sa Idaho
22 pag-aaral para sa Obesity ang naghahanap ng mga kalahok sa mga site sa Idaho.
Mga Lungsod sa Idaho
Opisyal na teksto ng pag-aaral (English)
Home Self-administration of Maridebart Cafraglutide With Autoinjector in Adults Living With Obesity or Overweight
- Solaris Clinical Research, Meridian
Nagre-recruitPhase 3
Edad 18 hanggang 99 · Lahat ng kasarian · Na-update Nob 9, 2026 · NCT07871409A Clinical Study to Evaluate the Effects of Enicepatide (RO7795068) in Participants With Obesity or Overweight and Type 2 Diabetes
- Elite Clinical Trials, Blackfoot
Nagre-recruitPhase 3
Edad 18 pataas · Lahat ng kasarian · Na-update Nob 9, 2026 · NCT07351058Efficacy, Safety and Tolerability of Switching From Glucagon-like Peptide-1 Receptor Agonists (GLP-1RA) to Maridebart Cafraglutide in Adults With Obesity or Overweight (MARITIME-SWITCH)
- Solaris Clinical Research, Meridian
Nagre-recruitPhase 3
Edad 18 hanggang 99 · Lahat ng kasarian · Na-update Nob 6, 2026 · NCT07575399A Phase III Study to Evaluate the Efficacy and Safety of Petrelintide in Participants With Overweight or Obesity
- Solaris Clinical Research (SCR), Meridian
Nagre-recruitPhase 3
Edad 18 pataas · Lahat ng kasarian · Na-update Nob 5, 2026 · NCT07843498A Study of Eloralintide (LY3841136) in Participants With Persistent Obesity Who Are Treated With a Weekly Incretin
- Family First Medical Center, Idaho Falls
Nagre-recruitPhase 3
Edad 18 pataas · Lahat ng kasarian · Na-update Nob 4, 2026 · NCT07392190Efficacy and Safety of Eloralintide (LY3841136) in Participants With Osteoarthritis Knee Pain and Obesity or Overweight
- Medical Research Partners, Ammon
Nagre-recruitPhase 3
Edad 18 pataas · Lahat ng kasarian · Na-update Nob 4, 2026 · NCT07353931Mirikizumab and Tirzepatide Administered in Adult Participants With Moderately to Severely Active Crohn's Disease and Obesity or Overweight
- Grand Teton Research Group, Idaho Falls
Nagre-recruitPhase 3
Edad 18 hanggang 70 · Lahat ng kasarian · Na-update Nob 4, 2026 · NCT06937099Mirikizumab Administered at the Same Time as Tirzepatide in Adult Participants With Moderately to Severely Active Ulcerative Colitis and Obesity or Overweight: Phase 3b Study
- Grand Teton Research Group, Idaho Falls
Nagre-recruitPhase 3
Edad 18 hanggang 70 · Lahat ng kasarian · Na-update Nob 4, 2026 · NCT06937086A Study of LY3457263 Compared With Placebo in Participants With Type 2 Diabetes on a Stable Dose of Semaglutide or Tirzepatide
- Elite Clinical Trials, Rexburg
Nagre-recruitPhase 2
Edad 18 hanggang 75 · Lahat ng kasarian · Na-update Nob 4, 2026 · NCT06897475Maridebart Cafraglutide in Heart Failure With Preserved or Mildly Reduced Ejection Fraction and Obesity
- High Desert Heart and Vascular, Meridian
Nagre-recruitPhase 3
Edad 18 hanggang 99 · Lahat ng kasarian · Na-update Okt 29, 2026 · NCT07037459Safety and Efficacy of ABBV-295 in Adults With Obesity or Overweight With Weight-Related Comorbidities
- Elite Clinical Trials - Blackfoot /ID# 282042, Blackfoot
Nagre-recruitPhase 2
Edad 18 hanggang 75 · Lahat ng kasarian · Na-update Okt 27, 2026 · NCT07752979A Study of Aleniglipron in Adults With Obesity or Overweight and Type 2 Diabetes Mellitus (ACCOMPLISH-2)
- ACCOMPLISH-2 Research Site, Meridian
Nagre-recruitPhase 3Malugod na tinatanggap ang malusog na boluntaryo
Edad 18 hanggang 79 · Lahat ng kasarian · Na-update Okt 20, 2026 · NCT07654374A Study to Investigate Weight Management With Macupatide and Eloralintide, Alone or in Combination, in Adult Participants With Obesity or Overweight
- Medical Research Partners, Ammon
Nagre-recruitPhase 2
Edad 18 hanggang 75 · Lahat ng kasarian · Na-update Okt 8, 2026 · NCT07589608A Master Protocol Study (LY900038) of Multiple Intervention-Specific-Appendices (ISAs) in Adult Participants With Obesity or Overweight
- Medical Research Partners, Ammon
Nagre-recruitPhase 2
Edad 18 hanggang 75 · Lahat ng kasarian · Na-update Okt 7, 2026 · NCT06143956Extension Trial to Evaluate the Long-term Efficacy, Safety, and Tolerability of Maridebart Cafraglutide (MARITIME-1-EXTENSION)
- Solaris Clinical Research, Meridian
Nagre-recruitPhase 3
Edad 18 hanggang 99 · Lahat ng kasarian · Na-update Okt 5, 2026 · NCT07684235A Research Study on How Well Cagrilintide and CagriSema Work in Children and Adolescents With Excess Body Weight
- Solaris Clinical Research, Meridian
Nagre-recruitPhase 3
Edad 8 hanggang 18 · Lahat ng kasarian · Na-update Set 30, 2026 · NCT07253285A Study of Once-daily Oral ASC30 to Evaluate the Efficacy and Safety in Adult Participants With Obesity or Overweight With Type 2 Diabetes
- AURORA-2 Clinical Site, Boise
Nagre-recruitPhase 3
Edad 18 pataas · Lahat ng kasarian · Na-update Set 16, 2026 · NCT07743450A Study of Once-daily Oral ASC30 to Evaluate the Efficacy and Safety in Adult Participants With Obesity or Overweight With Weight-Related Comorbidities
- AURORA-1 Clinical Site, Boise
Nagre-recruitPhase 3
Edad 18 pataas · Lahat ng kasarian · Na-update Set 16, 2026 · NCT07743463A Research Study to Look at How Well NNC0487-0111 Works Compared to Placebo in People With Heart Failure and Obesity
- High Desert Heart and Vascular PLLC, Meridian
- St. Luke's Idaho Cardiology Associates, Meridian
Nagre-recruitPhase 3
Edad 18 pataas · Lahat ng kasarian · Na-update Ago 18, 2026 · NCT07567001Efficacy and Safety of Aleniglipron in Participants With Obesity or Overweight With a Weight-Related Comorbidity (ACCOMPLISH-1)
- ACCOMPLISH-1 Research Site, Meridian
- ACCOMPLISH-1 Research Site, Rexburg
Nagre-recruitPhase 3
Edad 18 hanggang 79 · Lahat ng kasarian · Na-update Ago 10, 2026 · NCT07654361Functional Improvement in OSA and COPD With a Telehealth LifeStyle and Exercise Intervention
- Boise VA Medical Center, Boise
Nagre-recruit
Edad 18 pataas · Lahat ng kasarian · Na-update Hul 22, 2026 · NCT06390345A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Knee Osteoarthritis Lose Weight and Reduce Pain
- Elite Clinical Trials, Blackfoot
Nagre-recruitPhase 3
Edad 18 pataas · Lahat ng kasarian · Na-update Hul 9, 2026 · NCT07481630Mula sa ClinicalTrials.gov, na-kuha noong Nob 15, 2026. Ang bawat pag-aaral ay may sariling pamantayan sa eligibility; ang koponan ng pag-aaral ang magdedesisyon kung sino ang makakasali.